To validate this, we conducted western blot analyses in VCaP cells treated with 1 μm UBX‐390 for 4, 24, or 72 h and found a decrease in the levels of proteins related to the AR pathway and prostate cancer biology (i.e., Myc and NK3 homeobox 1 (NKX3.1)) over time following treatment (Figure S2, Supporting Information). The gene discussed is NKX3-1; the disease is prostate carcinoma.